At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
Capecitabine +2 moredrug
Likely dose
Capecitabine 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Safety and Efficacy Study of Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Metastatic or Unresectable Sarcomatoid Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Capecitabine, Gemcitabine, and 1 other intervention for Renal Cell Carcinoma and Kidney Cancer. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if the combination of 3 drugs (gemcitabine, capecitabine, and bevacizumab) can help to control metastatic or unresectable renal cell carcinoma. The safety of this drug combination will also be tested.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma, Kidney Cancer
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedJul 2007
Primary CompletionMay 2016
TodayJul 2026
First PostedJul 4, 2007
Enrollment StartJul 1, 2007
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 19.0 years ago
Interventions
Capecitabinedrug
800 mg/m\^2 By Mouth Twice Daily On Days 1-21.
Gemcitabinedrug
900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.
Bevacizumabdrug
10 mg/kg By Vein On Days 1 and 15.